ViiV Healthcare

News

Four women, seen from the back, hold each other behind each's back

Campaign seeks to plug HIV care gap for UK women

ViiV's campaign wants communication between women and healthcare workers about HIV to move beyond harmful stereotypes and 'risk' labels.

News

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

GSK's Dovato matches rival Biktarvy with less weight gain

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain.

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

News

China clears ViiV, J&J injectable HIV treatment

ViiV Healthcare and Johnson & Johnson have been granted approval in China for a long-acting HIV therapy that frees patients from the need to take daily pills to keep t

Campaign seeks to plug HIV care gap for UK women

ViiV's bimonthly HIV PrEP jab cleared for use by NHS

FDA sets June date for Gilead's twice-yearly HIV PrEP

GSK's Dovato matches rival Biktarvy with less weight gain

Gilead and MSD say weekly oral therapy controls HIV

China clears ViiV, J&J injectable HIV treatment

Veraxa says delayed US listing is back on track

How to meet your physicians where they are online

ViiV Healthcare

Editor's Picks